The Clinical Impact of the Basophil Activation Test to Diagnose Food Allergy

Sponsor

King's College London (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT05309772

Collaborator

Sandwell & West Birmingham Hospitals NHS Trust (Other), Cambridge University Hospitals NHS Foundation Trust (Other), NHS Lothian (Other), University Hospitals, Leicester (Other), Guy's and St Thomas' NHS Foundation Trust (Other), University College London Hospitals (Other), King's College Hospital NHS Trust (Other), Manchester University NHS Foundation Trust (Other), Newcastle-upon-Tyne Hospitals NHS Trust (Other), Sheffield Children's NHS Foundation Trust (Other), University Hospital Southampton NHS Foundation Trust (Other)

398

Enrollment

Locations

Arms

Anticipated Duration (Months)

36.2

Patients Per Site

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The BAT Impact study is a prospective multicentre study in the UK using a biomarker-led study design to compare the incidence of adverse events (defined as allergic reactions during oral food challenges) in a randomized-controlled trial. Patients will either follow the standard-of-care (i.e. an oral food challenge in case of equivocal SPT/sIgE) or follow a basophil activation test (BAT)/mast cell activation test (MAT)-based strategy, i.e. patients with a positive BAT or MAT are dispensed of an oral food challenge (OFC) and patients with a negative BAT/MAT undergo an OFC.

Condition or Disease	Intervention/Treatment	Phase
Food Allergy Food Allergy in Infants Food Allergy in Children Food Allergen Sensitisation Milk Allergy Egg Allergy Nut Allergy	Diagnostic Test: Basophil activation test (BAT) Diagnostic Test: Oral food challenge (OFC)	N/A

Detailed Description

Children aged 6 months to 15 years requiring an oral food challenge to one of the study foods (milk, egg, peanut, sesame or cashew nut) will be invited to participate in the study.

Eleven centres across the UK will be recruiting participants and perforning clinical procedures, such as skin prick testing and oral food challenges (OFC), as per standard clinical care.

Participants will be randomised 4:5 to either have the standard-of-care, i.e. oral food challenge to the suspected food, or take BAT (MAT if BAT inconclusive) into account to decide whether or not OFC will be required: if BAT/MAT is positive, food allergy will be confirmed without doing OFC; if BAT/MAT is negative, participants in the biomarker arm will undergo OFC.

The primary outcome is the proportion of positive OFC in the biomarker arm compared with the standard-of-care arm.

Secondary outcomes are: number of OFC, quality of life, anxiety and costs associated with the diagnostic work-up.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

398 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Intervention Model Description:

Patients will be randomised using a 4:5 allocation between standard-of-care/biomarker arms. Stratified randomisation will be adopted according to recruiting centre, using a web-based allocation system.Patients will be randomised using a 4:5 allocation between standard-of-care/biomarker arms. Stratified randomisation will be adopted according to recruiting centre, using a web-based allocation system.

Masking:

Triple (Participant, Care Provider, Investigator)

Primary Purpose:

Diagnostic

Official Title:

Randomised Controlled Multicentre Trial on the Clinical Impact of the Basophil Activation Test and the Mast Cell Activation Test as Food Allergy Biomarkers in Children and Young People

Anticipated Study Start Date :

Sep 1, 2022

Anticipated Primary Completion Date :

Sep 1, 2024

Anticipated Study Completion Date :

Sep 1, 2025

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Biomarker arm All participants will have blood taken to test for BAT/MAT. Participants with a positive BAT/MAT will dispense from oral food challenge (OFC). Participants with negative or inconclusive BAT/MAT will undergo OFC.	Diagnostic Test: Basophil activation test (BAT) Basophils and mast cells are the key drivers of food allergic reactions and anaphylaxis to foods. The study team have developed new tests that measure the reaction of mast cells and basophils by flow cytometry following stimulation with allergen, the BAT and the MAT: • BAT uses fresh whole blood from patients added to allergen and antibodies in a test tube. The tube containing the allergic cells are then analysed one by one to estimate how many and how much express activation markers on their surface, CD63 and CD203c. MAT uses a human mast cell line (LAD2 cells) which are human mast cells grown in the laboratory to which patients' plasma is added in order to mimic the patients' own mast cells. Sensitised LAD2 cells are then stimulated with allergen or controls and analysed by flow cytometry to assess the expression of the activation marker CD63 on the cell surface, similar to what happens in the BAT. Results of MAT will be considered only in cases of non-responding basophils. Other Names: Mast cell activation test (MAT) Diagnostic Test: Oral food challenge (OFC) Consumption of the food suspected of causing an allergic reaction in a medically supervised environment, starting with small amounts and progressively increasing the dose at regular intervals up to a cumulative dose corresponding to an age-appropriate portion of the food.
Active Comparator: Standard-of-care arm All participants in the standard-of-care arm will have blood taken to test for BAT/MAT. Regardless of the result of BAT/MAT, all participants in this arm will undergo an oral food challenge, as per the current standard-of-care.	Diagnostic Test: Basophil activation test (BAT) Basophils and mast cells are the key drivers of food allergic reactions and anaphylaxis to foods. The study team have developed new tests that measure the reaction of mast cells and basophils by flow cytometry following stimulation with allergen, the BAT and the MAT: • BAT uses fresh whole blood from patients added to allergen and antibodies in a test tube. The tube containing the allergic cells are then analysed one by one to estimate how many and how much express activation markers on their surface, CD63 and CD203c. MAT uses a human mast cell line (LAD2 cells) which are human mast cells grown in the laboratory to which patients' plasma is added in order to mimic the patients' own mast cells. Sensitised LAD2 cells are then stimulated with allergen or controls and analysed by flow cytometry to assess the expression of the activation marker CD63 on the cell surface, similar to what happens in the BAT. Results of MAT will be considered only in cases of non-responding basophils. Other Names: Mast cell activation test (MAT) Diagnostic Test: Oral food challenge (OFC) Consumption of the food suspected of causing an allergic reaction in a medically supervised environment, starting with small amounts and progressively increasing the dose at regular intervals up to a cumulative dose corresponding to an age-appropriate portion of the food.

Arm

Intervention/Treatment

Experimental: Biomarker arm

All participants will have blood taken to test for BAT/MAT. Participants with a positive BAT/MAT will dispense from oral food challenge (OFC). Participants with negative or inconclusive BAT/MAT will undergo OFC.

Diagnostic Test: Basophil activation test (BAT)

Basophils and mast cells are the key drivers of food allergic reactions and anaphylaxis to foods. The study team have developed new tests that measure the reaction of mast cells and basophils by flow cytometry following stimulation with allergen, the BAT and the MAT: • BAT uses fresh whole blood from patients added to allergen and antibodies in a test tube. The tube containing the allergic cells are then analysed one by one to estimate how many and how much express activation markers on their surface, CD63 and CD203c. MAT uses a human mast cell line (LAD2 cells) which are human mast cells grown in the laboratory to which patients' plasma is added in order to mimic the patients' own mast cells. Sensitised LAD2 cells are then stimulated with allergen or controls and analysed by flow cytometry to assess the expression of the activation marker CD63 on the cell surface, similar to what happens in the BAT. Results of MAT will be considered only in cases of non-responding basophils.

Other Names:

Mast cell activation test (MAT)

Diagnostic Test: Oral food challenge (OFC)

Consumption of the food suspected of causing an allergic reaction in a medically supervised environment, starting with small amounts and progressively increasing the dose at regular intervals up to a cumulative dose corresponding to an age-appropriate portion of the food.

Active Comparator: Standard-of-care arm

All participants in the standard-of-care arm will have blood taken to test for BAT/MAT. Regardless of the result of BAT/MAT, all participants in this arm will undergo an oral food challenge, as per the current standard-of-care.

Diagnostic Test: Basophil activation test (BAT)

Other Names:

Mast cell activation test (MAT)

Diagnostic Test: Oral food challenge (OFC)

Outcome Measures

Primary Outcome Measures

The proportion of positive oral food challenges in the biomarker arm (BAT ± MAT) compared to the standard-of-care arm [Up to 1 year]
Comparison of the ratio of positive oral food challenges in the biomarker arm compared to the standard-of-care arm.
Number of OFCs in the biomarker arm (BAT ± MAT) compared to the standard-of-care arm [Up to 1 year]
Comparison of the ratio of OFCs in the biomarker arm compared to the standard-of-care arm.

Secondary Outcome Measures

The quality of life of children and parents at the start and at the end of the diagnostic work-up for food allergy as assessed by the Food Allergy Quality of Life Questionnaire. [Up to 1.5 years]
Change in quality of life score at the start and end of diagnostic work-up.
Anxiety levels of parents and children before and after diagnostic work-up as assessed by the Hospital Anxiety and Depression Questionnaire. [Up to 1.5 years]
Change in anxiety score before and after diagnostic work-up.
Anxiety levels of parents and children before and after diagnostic work-up as assessed by the State Trait Anxiety Inventory. [Up to 1.5 years]
Change in anxiety score before and after diagnostic work-up.
NHS and societal costs of food allergies during the diagnostic assessment, as measured through a bespoke form. [Up to 1.5 years]
NHS and societal costs during the six weeks before and six weeks after diagnostic work-up.

Eligibility Criteria

Criteria

Ages Eligible for Study:

6 Months to 15 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Children and young people aged 6 months to 15 years
Suspected allergy to one of the study foods (peanut, cow's milk, egg, cashew, sesame)
defined as:
history of clinical reaction or
evidence of IgE sensitisation (SPT>0mm and/or specific IgE>=0.10 KU/L) to the respective food or
reassessment for possible resolution of allergy to the specific food following previous diagnosis of food allergy
Need for an oral food challengeOFC to the study food
Oral food challengeOFC to reach amount of food protein in a typical portion size for child's age
Consent from adults with parental responsibility and assent from children and young people in an age appropriate form.

Exclusion Criteria:

Clinically significant chronic illness other than atopic diseases;
Previous history of severe life-threatening reaction to the suspected food with documented decrease in oxygen saturation (<90%), hypotension (≥20% reduction in systolic blood pressure) and/or admission to intensive care;
Unwillingness to comply with study procedures, namely to undergo a diagnostic food challenge;
Contra-indication for diagnostic food challenge, namely:
Uncontrolled atopic diseases (e.g. eczema, asthma, rhinitis);
Chronic medical conditions that pose significant risk in the event of anaphylaxis or treatment of anaphylaxis (e.g. cardiac disease, severe lung disease, pregnancy, mastocytosis);
Inability to discontinue medications that might interfere with assessment or safety (e.g. antihistamines, β-agonists, β-blockers, NSAIDs, ACE inhibitor, antacids);
Recent (within 7-14 days) treatment with systemic steroids or prolonged high-dose systemic steroids or immunosuppressants;
Undergoing treatment with omalizumab, food or inhalant allergen immunotherapy or other systemic immunomodulatory treatment;
Inability to stop anti-histamines prior to SPT or OFC.

Contacts and Locations

Locations

	Site	City	Country
1	Sandwell and West Birmingham Hospital	Birmingham	United Kingdom
2	Addenbrookes Hospital	Cambridge	United Kingdom
3	Royal Hospital for Children and Young People	Edinburgh	United Kingdom
4	Leicester Royal Infirmary	Leicester	United Kingdom
5	Evelina London Children's Hospital	London	United Kingdom
6	King's College Hospital	London	United Kingdom
7	University College London Hospital	London	United Kingdom
8	Royal Manchester Children's Hospital	Manchester	United Kingdom
9	Great North Children's Hospital	Newcastle	United Kingdom
10	Sheffield Children's Hospital	Sheffield	United Kingdom
11	University Hospital Southampton	Southampton	United Kingdom